Track Arcus Biosciences, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Arcus Biosciences, Inc. RCUS · Stock Open Arcus Biosciences, Inc. in new tab

17.43 USD
EPS
-3.64
P/B
6.33
ROE
-114.11
Beta
1.09
Target Price
41.00 USD
Arcus Biosciences, Inc. logo

Arcus Biosciences, Inc.

🧾 Earnings Recap – Q2 2026

Arcus shares declined 1.6% following the Q2 report as investors digested moderate progress in clinical development without new catalysts or positive updates on near-term financial outlook; the cautious tone on timing and upcoming milestones likely tempered enthusiasm.

  • Casdatifan remains the centerpiece, with ongoing Phase III trials (PEAK-1 enrolling through year-end) targeting second-line clear cell RCC.
  • Management emphasized multiple collaborations with bispecific anti-PD-1/VEGF antibodies, expanding options in frontline settings but without definitive efficacy data yet.
  • The failure of Merck’s competitor LITESPARK-012 provides a clearer path for casdatifan but no immediate impact on Arcus’s financials or patient uptake.
  • Plans to start a frontline registrational Phase III trial (PEAK-20) remain on track for late 2026, maintaining development timelines but offering no acceleration.
  • No updated financial guidance or margin commentary was provided to suggest a near-term catalyst or relief from pipeline-related uncertainties.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 24, 2027
EPS-3.64
Book Value2.81
Price to Book6.33
Debt/Equity67.32
% Insiders25.466%
Growth
Revenue Growth-0.65%
Estimates
Forward P/E-5.75
Forward EPS-3.09
Target Mean Price41.00

DCF valuation

Model fair value for Arcus Biosciences, Inc. (RCUS)
Result
Sign in to run the valuation for RCUS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
12 analysts · consensus Strong buy · mean target 41.00 USD (low 23.00, high 50.00) · as of 12 Nov 2026
Low 23.00
Mean 41.00
High 50.00
Price 17.43
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Arcus Biosciences, Inc. Logo Arcus Biosciences, Inc. Analysis (RCUS)

United States Health Care Official Website Stock

Is Arcus Biosciences, Inc. a good investment? Arcus Biosciences, Inc. (RCUS) is currently trading at 17.43 USD. Market analysts have a consensus price target of 41.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: Arcus Biosciences, Inc. is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is -3.09.

Investor FAQ

Does Arcus Biosciences, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Arcus Biosciences, Inc.?

Arcus Biosciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of -3.64.

Company Profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Exchange Ticker
NYQ (United States) RCUS
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion